Summit is looking to reach potential clinical trial volunteers online via a new resource on utrophin modulation, whose potential as a treatment for Duchenne muscular dystrophy (DMD) the UK biopharma is investigating.
Utrophintrials.com provides information on utrophin and Summit’s utrophin modulator clinical trials, including for its lead candidate the orphan drug ezutromid, which is currently in a phase IIa trial.
Glyn Edwards, Summit’s chief executive officer, said: “We recognise the dedication and engagement of the DMD community in the search for solutions for this fatal muscle wasting disease, and with this website, seek to provide this community with access to important information about our utrophin modulator programme and clinical trials.
“We are committed to broadening our relationship with the DMD community as we advance ezutromid and other utrophin modulators, which may have the potential to treat all patients with DMD.”
A progressive muscle wasting disease, DMD affects around 50,000 boys and young men in the developed world and currently has no cure.
If Summit can bring ezutromid to market it will compete with PCT Therapeutics’ Translarna, which was recommended by NICE in England and Wales earlier this year, and potentially Santhera Pharmaceuticals’ delayed Raxone.
